Form 4 for ADMA ADMA BIOLOGICS, INC.

Accepted 2024-12-02 00:00:00 ET · period of report 2024-11-27 · accession 0001140361-24-048224 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DI	2024-12-02	2024-11-27	ADMA	ELMS STEVE	Dir	M - OptEx	$10.80	+9,000	2.12M	+0.4%	+$97.2K
D	2024-12-02	2024-11-27	ADMA	ELMS STEVE	Dir	M - OptEx	$0.00	-9,000	0	-100%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-11-27	M	A	9,000	$10.80	2,124,671	I See footnote	—	—	(F1) These shares are owned by Aisling Capital II LP ("Aisling"), which is a fund that was established in 2007 with a 10-year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Company and Aisling Partners' ownership of the Company's options, except to the extent of his pecuniary interest therein.
2	Derivative	Stock Option (Right to Buy)	2024-11-27	M	D	9,000	$0.00	0	D	$10.80 · — to 2025-01-30	9,000 Common Stock	(F3) The Reporting Person is exercising these options due to their near-term expiration date. (F4) These options vested monthly over a period of 24 months from the date of grant, becoming fully vested on January 30, 2017.